![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
PJ Tiseo, J Cheng, GW Pasternak and CE Inturrisi
Department of Pharmacology, Cornell University Medical College, New York, New York.
Recent reports have demonstrated that the coadministration of morphine with an N-methyl-D-aspartate (NMDA) receptor antagonist can attenuate and/or reverse the development of morphine tolerance. In the present study we used an experimental tolerance paradigm using morphine pellets (75 mg) to produce an 1-fold shift in the morphine dose-response curve in rats. Coadministration of the competitive NMDA receptor antagonist LY274614 [(+-)-6-phosphonomethyl-decahydroisoquinolin-3-carboxylic acid] via continuous s.c. infusion (24 mg/kg/24 hr) significantly attenuated the development of morphine tolerance. In addition, animals made tolerant to morphine and then infused with LY274614 (24 mg/kg/24 hr) regained their analgesic sensitivity to morphine more rapidly than morphine-tolerant animals given a saline infusion. To determine whether LY274614 treatment modifies the subsequent development of tolerance, LY274614 was administered to nontolerant animals for 1 week. One week after LY274614 treatment was discontinued the animals were challenged with morphine and then implanted with morphine pellets. Neither the expression of morphine analgesia nor the development of morphine tolerance differed when LY274614- and saline-treated animals were compared. The infusion of LY274614 for 7 days did not increase the affinity or density of mu, delta, kappa-1 or kappa-3 opioid receptors in rat brain homogenates as measured by ligand binding assays. Additionally, the IC50 values for LY274614 in mu-1, mu-2, delta, kappa- 1 or kappa-3 ligand binding assays were greater than 10 microM. Taken together these results demonstrate that the competitive NMDA receptor antagonist LY274614 can both attenuate and reverse the development of morphine tolerance.(ABSTRACT TRUNCATED AT 250 WORDS)
This article has been cited by other articles:
|
|
 |
|
  N. Shimoyama, M. Shimoyama, A. M. Davis, D. T. Monaghan, and C. E. Inturrisi An Antisense Oligonucleotide to the N-Methyl-D-aspartate (NMDA) Subunit NMDAR1 Attenuates NMDA-Induced Nociception, Hyperalgesia, and Morphine Tolerance J. Pharmacol. Exp. Ther., February 1, 2005; 312(2): 834 - 840. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Martin, A. Guadano-Ferraz, B. Morte, S. Ahmed, G. F. Koob, L. de Lecea, and G. R. Siggins Chronic Morphine Treatment Alters N-Methyl-D-aspartate Receptors in Freshly Isolated Neurons from Nucleus Accumbens J. Pharmacol. Exp. Ther., October 1, 2004; 311(1): 265 - 273. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. W. Vanderah, N. M. H. Suenaga, M. H. Ossipov, T. P. Malan Jr, J. Lai, and F. Porreca Tonic Descending Facilitation from the Rostral Ventromedial Medulla Mediates Opioid-Induced Abnormal Pain and Antinociceptive Tolerance J. Neurosci., January 1, 2001; 21(1): 279 - 286. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. W. Vanderah, L. R. Gardell, S. E. Burgess, M. Ibrahim, A. Dogrul, C.-M. Zhong, E.-T. Zhang, T. P. Malan Jr, M. H. Ossipov, J. Lai, et al. Dynorphin Promotes Abnormal Pain and Spinal Opioid Antinociceptive Tolerance J. Neurosci., September 15, 2000; 20(18): 7074 - 7079. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Miyamoto, Y. Saito, Y. Kirihara, K. Hara, S. Sakura, and Y. Kosaka Spinal Coadministration of Ketamine Reduces the Development of Tolerance to Visceral As Well As Somatic Antinociception During Spinal Morphine Infusion Anesth. Analg., January 1, 2000; 90(1): 136 - 136. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Martin, S. H. Ahmed, T. Blank, J. Spiess, G. F. Koob, and G. R. Siggins Chronic Morphine Treatment Alters NMDA Receptor-Mediated Synaptic Transmission in the Nucleus Accumbens J. Neurosci., October 15, 1999; 19(20): 9081 - 9089. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. A. Fairbanks and G. L. Wilcox Spinal Antinociceptive Synergism between Morphine and Clonidine Persists in Mice Made Acutely or Chronically Tolerant to Morphine J. Pharmacol. Exp. Ther., March 1, 1999; 288(3): 1107 - 1116. [Abstract] [Full Text]
|
|
|
|
 |
|
 G. Martin, Z. Nie, and G. R. Siggins Metabotropic Glutamate Receptors Regulate N-Methyl-D-Aspartate-Mediated Synaptic Transmission in Nucleus Accumbens J Neurophysiol, December 1, 1997; 78(6): 3028 - 3038. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Kest, G. McLemore, B. Kao, and C. E. Inturrisi The Competitive alpha -Amino-3-Hydroxy-5-Methylisoxazole-4-Propionate Receptor Antagonist LY293558 Attenuates and Reverses Analgesic Tolerance to Morphine But Not to Delta or Kappa Opioids J. Pharmacol. Exp. Ther., December 1, 1997; 283(3): 1249 - 1255. [Abstract] [Full Text]
|
|
|
|
|
|
C. A. Fairbanks and G. L. Wilcox Acute Tolerance To Spinally Administered Morphine Compares Mechanistically with Chronically Induced Morphine Tolerance J. Pharmacol. Exp. Ther., September 1, 1997; 282(3): 1408 - 1417. [Abstract] [Full Text]
|
|
|
|
|
|
S. A. Dunbar and T. L. Yaksh J. Pharmacol. Exp. Ther., June 1, 1997; 281(3): 1219 - 1225. [Abstract] [Full Text]
|
|
|
|
 |
|
 Y.-C. Cai, L. Ma, G.-H. Fan, J. Zhao, L.-Z. Jiang, and G. Pei Activation of N-Methyl-D-Aspartate Receptor Attenuates Acute Responsiveness of delta -Opioid Receptors Mol. Pharmacol., April 1, 1997; 51(4): 583 - 587. [Abstract] [Full Text]
|
|
|
|
|
|
P. Popik and W. Danysz Inhibition of Reinforcing Effects of Morphine and Motivational Aspects of Naloxone-Precipitated Opioid Withdrawal by N-Methyl-D-aspartate Receptor Antagonist, Memantine J. Pharmacol. Exp. Ther., February 1, 1997; 280(2): 854 - 865. [Abstract] [Full Text]
|
|
 |
 |
 |
|
 |
 |
 |
